TYRA-430

N/A

Report date: 2025/04/20 20:00:03
NME

Base Information

Drug NameTYRA-430
Drug Alias NameTYRA-430
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 4 antagonists
TargetsFibroblast growth factor receptor 3Fibroblast growth factor receptor 4
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[4] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesTyra Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesTyra Biosciences Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Hepatocellular
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A